Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

BP1, a putative signature marker for inflammatory breast cancer and tumor aggressiveness.

Man YG, Schwartz A, Levine PH, Teal C, Berg PE.

Cancer Biomark. 2009;5(1):9-17. doi: 10.3233/CBM-2009-0563.

PMID:
19242057
2.

Role of E-cadherins in development of lymphatic tumor emboli.

Gupta A, Deshpande CG, Badve S.

Cancer. 2003 May 1;97(9):2341-7.

3.

Expression of BP1, a novel homeobox gene, correlates with breast cancer progression and invasion.

Man YG, Fu SW, Schwartz A, Pinzone JJ, Simmens SJ, Berg PE.

Breast Cancer Res Treat. 2005 Apr;90(3):241-7.

PMID:
15830137
4.

Persistent E-cadherin expression in inflammatory breast cancer.

Kleer CG, van Golen KL, Braun T, Merajver SD.

Mod Pathol. 2001 May;14(5):458-64.

5.
6.

Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin.

Ben Hamida A, Labidi IS, Mrad K, Charafe-Jauffret E, Ben Arab S, Esterni B, Xerri L, Viens P, Bertucci F, Birnbaum D, Jacquemier J.

BMC Cancer. 2008 Jan 29;8:28. doi: 10.1186/1471-2407-8-28.

7.

BP1, a homeoprotein, is significantly expressed in prostate adenocarcinoma and is concordant with prostatic intraepithelial neoplasia.

Schwartz AM, Man YG, Rezaei MK, Simmens SJ, Berg PE.

Mod Pathol. 2009 Jan;22(1):1-6. doi: 10.1038/modpathol.2008.168.

8.

Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study.

Van der Auwera I, Van den Eynden GG, Colpaert CG, Van Laere SJ, van Dam P, Van Marck EA, Dirix LY, Vermeulen PB.

Clin Cancer Res. 2005 Nov 1;11(21):7637-42.

9.

Significance of pathological evaluation for lymphatic vessel invasion in invasive breast cancer.

Ito M, Moriya T, Ishida T, Usami S, Kasajima A, Sasano H, Ohuchi N.

Breast Cancer. 2007;14(4):381-7.

10.

D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma.

Rabban JT, Chen YY.

Hum Pathol. 2008 Feb;39(2):175-83. doi: 10.1016/j.humpath.2007.06.018.

PMID:
18206495
11.

Amplification of the BP1 homeobox gene in breast cancer.

Cavalli LR, Man YG, Schwartz AM, Rone JD, Zhang Y, Urban CA, Lima RS, Haddad BR, Berg PE.

Cancer Genet Cytogenet. 2008 Nov;187(1):19-24. doi: 10.1016/j.cancergencyto.2008.07.004.

PMID:
18992636
12.

Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue.

Monteagudo C, Merino MJ, San-Juan J, Liotta LA, Stetler-Stevenson WG.

Am J Pathol. 1990 Mar;136(3):585-92.

13.

AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas.

Sitterding SM, Wiseman WR, Schiller CL, Luan C, Chen F, Moyano JV, Watkin WG, Wiley EL, Cryns VL, Diaz LK.

Ann Diagn Pathol. 2008 Feb;12(1):33-40. doi: 10.1016/j.anndiagpath.2007.02.004.

PMID:
18164413
14.

[Micrometastases of the axillary lymph nodes in breast cancer. An immunohistochemical study].

Ronay G, Tomesch A, Tulusan AH.

Pathologe. 1989 Sep;10(5):289-93. Russian. No abstract available.

PMID:
2477837
15.

ras p21 expression in the progression of breast cancer.

Fromowitz FB, Viola MV, Chao S, Oravez S, Mishriki Y, Finkel G, Grimson R, Lundy J.

Hum Pathol. 1987 Dec;18(12):1268-75.

PMID:
3315956
16.

Analysis of the immunohistochemical expression of mammaglobin A in primary breast carcinoma and lymph node metastasis.

Raica M, Cîmpean AM, Meche A, Alexa A, Suciu C, Mureşan A.

Rom J Morphol Embryol. 2009;50(3):341-7.

17.

FOXP3 expression of micrometastasis-positive sentinel nodes in breast cancer patients.

Matsuura K, Yamaguchi Y, Osaki A, Ohara M, Okita R, Emi A, Murakami S, Arihiro K.

Oncol Rep. 2009 Nov;22(5):1181-7.

PMID:
19787238
18.

HYOU1/Orp150 expression in breast cancer.

Stojadinovic A, Hooke JA, Shriver CD, Nissan A, Kovatich AJ, Kao TC, Ponniah S, Peoples GE, Moroni M.

Med Sci Monit. 2007 Nov;13(11):BR231-239.

PMID:
17968289
19.
Items per page

Supplemental Content

Support Center